Information Provided By: 
Fly News Breaks for October 15, 2018
ACRX
Oct 15, 2018 | 12:30 EDT
After AcelRx presented data from an enhanced application to an FDA expert panel one year after announcing a CRL on the original application for Dsuvia, H.C. Wainwright analyst Ed Arce now sees the drug being poised for approval following the panel's positive 10-3 vote. Ahead of what he sees as a Dsuvia launch in the first quarter of 2019, Arce raised his price target on AcelRx shares to $8 from $7 and keeps a Buy rating on the stock.
News For ACRX From the Last 2 Days
There are no results for your query ACRX
